Dr. Hur is the Herbert and Florence Irving Professor of Medicine and Epidemiology and the Director of Healthcare Innovations and Research at Columbia University Medical Center. He is a nationally recognized expert in cancer screening and the prevention of gastrointestinal cancers, and a leader within the National Cancer Institute consortium of researchers that work toward improving cancer management.
His research focuses on esophageal, gastric, and pancreatic disease and the use of data analytics and advanced machine learning to develop clinical prediction rules.
- Heavy Alcohol Use Is Associated With Gastric Cancer: Analysis of the National Health and Nutrition Examination Survey From 1999 to 2010
- Management of Gastric Intestinal Metaplasia
- Early liver transplantation for alcoholic hepatitis: Ready for primetime?
- Evidence-based endoscopic management of Barrett’s esophagus
- Endoscopic therapy versus surgery for T1 colon cancer: defining model clinical practice
- Screening for Upper Gastrointestinal Malignancies in the United States—Which Immigrant Groups Should Be Considered High-Risk?
- Garlic, Silver Bullets, and Surveillance Upper Endoscopy for Barrett’s Esophagus
- Risk factors for developing both primary breast and primary ovarian cancer: A systematic review
- Unsedated Colonoscopy: Impact on Quality Indicators
- Esophageal Capsule Endoscopy for Barrett’s Esophagus Screening: A Hard Pill to Swallow?
- Screening and surveillance for Barrett’s esophagus: current issues and future directions
- >Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles
- Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
- Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice